The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $49.79 in the prior trading day, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $46.85, down -5.90%. In other words, the price has decreased by -$5.90 from its previous closing price. On the day, 1.95 million shares were traded. CRSP stock price reached its highest trading level at $50.1 during the session, while it also had its lowest trading level at $46.84.
Ratios:
Our goal is to gain a better understanding of CRSP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.64 and its Current Ratio is at 21.64. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on August 06, 2024, Reiterated its Buy rating but revised its target price to $84 from $88 previously.
On August 02, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’24 when Kulkarni Samarth sold 30,000 shares for $55.62 per share. The transaction valued at 1,668,678 led to the insider holds 196,540 shares of the business.
KASINGER JAMES R. sold 1,089 shares of CRSP for $50,399 on Oct 14 ’24. The General Counsel and Secretary now owns 62,597 shares after completing the transaction at $46.28 per share. On Oct 14 ’24, another insider, Kulkarni Samarth, who serves as the Chief Executive Officer of the company, sold 4,293 shares for $46.28 each. As a result, the insider received 198,680 and left with 226,540 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 3998811648 and an Enterprise Value of 2290710528. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.72 while its Price-to-Book (P/B) ratio in mrq is 2.06. Its current Enterprise Value per Revenue stands at 11.294 whereas that against EBITDA is -7.317.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $43.42. The 50-Day Moving Average of the stock is -2.05%, while the 200-Day Moving Average is calculated to be -18.67%.
Shares Statistics:
The stock has traded on average 1.19M shares per day over the past 3-months and 2019590 shares per day over the last 10 days, according to various share statistics. A total of 85.35M shares are outstanding, with a floating share count of 81.64M. Insiders hold about 4.35% of the company’s shares, while institutions hold 65.87% stake in the company. Shares short for CRSP as of 1730332800 were 18587119 with a Short Ratio of 15.60, compared to 1727654400 on 17560892. Therefore, it implies a Short% of Shares Outstanding of 18587119 and a Short% of Float of 24.69.
Earnings Estimates
As of right now, 22.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.38, with high estimates of -$1.03 and low estimates of -$1.72.
Analysts are recommending an EPS of between -$4.66 and -$6.44 for the fiscal current year, implying an average EPS of -$5.14. EPS for the following year is -$5.01, with 25.0 analysts recommending between -$2.87 and -$6.84.
